Suven Pharmaceuticals Share Price

Suven Pharmaceuticals Share Price

NSE: COHANCE
|
Pharmaceuticals
|
S Cap
₹ 460.45
+₹22.45 (5.13%)
1D
Last updated 21 Sep, 2026, 15:59 IST

Suven Pharmaceuticals Share Price Today

As of 21 Sep 2026, Suven Pharmaceuticals share price is ₹460.45. The stock opened at ₹438.45, compared to its previous close of ₹438.00. During today's trading session, Suven Pharmaceuticals share price moved in the range of ₹435.55 to ₹482.25, with an average price of ₹458.90 for the day. Looking at its last 52-week, the stock has touched a low of ₹266.70 and a high of ₹932.00. On the performance front, Suven Pharmaceuticals share price has increased by 53.87% over the last six months and is down 49.37% on a year-on-year basis.

₹435.55
5.13% up today
₹482.25
1D LOW
1D HIGH

Suven Pharmaceuticals Returns Calculator

Circuit
L
H
₹350.40
₹525.60
52-week
L
H
₹266.70
₹932.00

About Suven Pharmaceuticals

Suven Pharmaceuticals Share Price
ISIN
INE03QK01018
Sector Market Cap
₹ 16,759.68 Cr

Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is an India-based technology-driven contract development and manufacturing organization (CDMO), providing integrated solutions in custom synthesis, process research and development (R&D), and manufacturing. The Company’s business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient (API) (including formulations). Its integrated CDMO model enables comprehensive molecule development and life cycle management for both pharmaceutical and specialty chemical partners. Its custom synthesis services include design and synthesis, synthesis of complex molecules, synthesis of reference standards, synthesis of impurities and metabolites, scale-up of existing synthetic routes, and process optimization and backward integration. Its process research services include route scouting, process development, process safety evaluation, analytical method development, and regulatory support.

Suven Pharmaceuticals Financial Highlights

  • Revenue: Suven Pharmaceuticals reported revenue of ₹2,302.64 crore in FY26 vs ₹2,677.71 crore in FY25. It showed a decrease of 14.01% on a yearly basis.
  • Operating Profit: Suven Pharmaceuticals reported an operating profit of ₹207.04 crore in FY26 vs ₹642.63 crore in FY25. It showed a decrease of 67.78% on a year-on-year basis.
  • Net Profit: Suven Pharmaceuticals reported a net profit of ₹150.12 crore in FY26 vs ₹484.24 crore in FY25. It showed a decrease of 69.00% on a yearly basis.

Suven Pharmaceuticals Quarterly Result Highlights

  • Suven Pharmaceuticals reported revenue of ₹434.51 crore in Jun 2026, compared with ₹617.28 crore in Mar 2026, representing a decrease of 29.61% on a quarter-on-quarter (QoQ) basis.
  • Suven Pharmaceuticals reported an operating loss of ₹42.87 crore in Jun 2026, compared with ₹19.91 crore in Mar 2026, representing a decrease of 315.32% on a quarter-on-quarter (QoQ) basis.
  • Suven Pharmaceuticals reported a loss of ₹45.19 crore in Jun 2026, compared with ₹8.31 crore in Mar 2026, reflecting a decrease of 643.80% on a QoQ basis.
  • The earnings per share (EPS) of Suven Pharmaceuticals stood at ₹4.69 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
57.49%
FII
6.50%
Other DII
1.88%
Retail and other
15.93%
Mutual funds
18.21%
Foreign Institutional Investor (FII)
FII shareholding by period
Sep 20256.51%
Dec 20256.02%
Mar 20265.59%
Jun 20266.50%
Mkt Cap Cr
16,759.70
P/E
286.31
P/B
4.28
ROE
5.05%
D/E
0.03
ROCE
5.47%
Div. Yield
0.00%
EPS(TTM)
5.98
Turnover
0.37
EV/EBITDA
52.30
Net Margin
11.26%
Op. Margin
23.13%
ROA
1.02%
Quick Ratio
2.24
Curr. Ratio
3.72
Based on fundamentals, this stock's
Step 4 of 5
Performance
Good
Cohance Life outperforming most market indices
Step 1 of 5
Valuation
Overvalued
Cohance Life appears overvalued compared to its peers
Step 1 of 5
Earnings
Very Poor
Cohance Life revenue, operating profits and net profits have been degrowing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,40,398.0036.355.2713.74%0.6117.33%93.240.87%0.4810.90
Divis Laboratories2,48,664.0085.0214.8415.32%0.0019.56%629.490.32%0.5598.19
Torrent Pharmaceuticals1,82,738.0084.7621.7325.49%1.6913.85%222.760.70%0.4958.70
Zydus Lifesciences1,15,012.0025.044.2418.59%0.3117.35%237.300.09%0.3335.38
Cipla1,10,794.0033.023.2211.27%0.0014.95%423.360.95%0.4543.52
Laurus Labs1,05,645.0096.8919.9316.77%0.4016.14%97.200.10%0.6713.72
Aurobindo Pharma99,828.1026.902.639.25%0.1911.76%394.820.23%0.3841.58
Lupin98,069.8017.674.3723.76%0.0424.88%659.000.84%0.57129.18
Dr. Reddy's Laboratories97,749.4030.712.5711.07%0.1812.54%377.950.68%0.4138.68
Mankind Pharma95,743.9046.305.8711.74%0.3413.13%396.980.04%0.4449.37

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

Suven Pharmaceuticals Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹2,268.55₹2,608.50₹1,051.35₹1,340.33
Other Income₹34.09₹69.21₹61.91₹46.36
Total Revenue₹2,302.64₹2,677.71₹1,113.26₹1,386.69
Total Expenses₹2,066.13₹2,019.30₹707.59₹826.96
Profit Before Tax₹207.04₹642.63₹405.67₹559.73
Tax₹56.92₹158.39₹105.39₹148.44
Profit After Tax₹150.12₹484.24₹300.28₹411.29
EPS - Basic₹4.69₹12.79₹11.80₹16.16
EPS - Diluted₹4.68₹12.68₹11.80₹16.16

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹207.04₹642.63₹405.67₹559.73
Income before WC changes₹415.33₹849.99₹421.02₹597.19
Change in Assets₹7.92₹7.15₹70.44₹59.22
Change in Liabilities₹12.84-₹7.88-₹23.03-₹53.45
Change in WC₹20.76-₹0.73₹47.41₹5.77
Cash flow from Operations₹368.32₹673.35₹358.48₹457.20
Cash flow from Investing-₹254.57-₹389.70-₹362.25-₹195.01
Cash flow from Financing-₹165.15-₹327.40-₹13.80-₹241.95
Total Cash Flow-₹51.40-₹43.75-₹17.57₹20.24
Cash (Start of the year)₹96.65₹138.32₹64.80₹44.56
Cash (End of the year)₹49.14₹96.65₹47.23₹64.80

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹3,933.38₹3,722.79₹990.90₹954.70
Current Assets₹1,796.26₹1,758.17₹1,263.19₹1,011.05
Total Assets₹5,729.64₹5,480.96₹2,254.09₹1,965.74
Current Liabilities₹645.93₹705.41₹106.90₹158.77
Net Current Asset₹1,150.33₹1,052.76₹1,156.29₹852.28
Non-Current Liabilities₹1,049.88₹982.67₹96.53₹71.79
Equity Capital₹4,033.83₹3,792.88₹2,050.66₹1,735.18
Total Equity & Liabilities₹5,729.64₹5,480.96₹2,254.09₹1,965.74

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹2,030.50₹2,504.43₹1,051.35₹1,330.08
Other Income₹44.73₹64.84₹56.61₹44.55
Total Revenue₹2,075.23₹2,569.27₹1,107.96₹1,374.63
Total Expenses₹1,732.13₹1,903.43₹707.54₹795.24
Profit Before Tax₹313.63₹650.06₹400.42₹579.39
Tax₹84.92₹158.88₹103.95₹146.79
Profit After Tax₹228.71₹491.18₹296.47₹432.60
EPS - Basic₹5.98₹12.89₹11.65₹16.99
EPS - Diluted₹5.97₹12.80₹11.65₹16.99

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹313.63₹650.06₹400.42₹579.39
Income before WC changes₹426.55₹838.83₹417.56₹615.08
Change in Assets₹27.45₹11.17₹90.72₹79.68
Change in Liabilities₹2.65₹9.08-₹23.56-₹56.15
Change in WC₹30.10₹20.25₹67.16₹23.53
Cash flow from Operations₹389.57₹686.23₹376.20₹492.82
Cash flow from Investing-₹204.29-₹455.35-₹362.40-₹236.86
Cash flow from Financing-₹202.78-₹309.91-₹39.99-₹243.14
Total Cash Flow-₹17.50-₹79.03-₹26.19₹12.81
Cash (Start of the year)₹30.61₹109.55₹44.65₹30.21
Cash (End of the year)₹13.11₹30.61₹18.46₹43.02

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹3,444.53₹3,423.54₹990.65₹1,003.21
Current Assets₹1,668.67₹1,613.51₹1,224.23₹955.12
Total Assets₹5,113.20₹5,037.05₹2,214.88₹1,958.33
Current Liabilities₹504.71₹553.78₹117.15₹154.18
Net Current Asset₹1,163.96₹1,059.73₹1,107.08₹800.94
Non-Current Liabilities₹128.38₹215.50₹69.38₹54.77
Equity Capital₹4,480.11₹4,267.77₹2,028.35₹1,749.38
Total Equity & Liabilities₹5,113.20₹5,037.05₹2,214.88₹1,958.33
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
460.45
200
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 200
Buy orders: 0%
Sell orders: 100%
Bearish
2
Neutral
6
Bullish
0
Slightly Bearish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
46.07
Neutral
ATR (14)
15.95
Neutral
STOCH(9,6)
49.21
Neutral
STOCH RSI (14)
47.36
Neutral
ADX(9)
27.19
Bearish
UO(9)
45.9
Neutral
ROC(12)
-4.78
Bearish
WillR(14)
-63.85
Neutral
Period
Simple value
Exponential vaue
5D
434.94
437.81
10D
442.11
441.23
20D
448.98
444.67
50D
443.49
442.89
100D
443.26
433.72
Volume trend — traded volume by day
21 Sep87L
18 Sep6L
17 Sep11L
16 Sep3L
15 Sep3L
Average22L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks
Suven Pharmaceuticals Share Price
Suven Pharmaceuticals
Pharmaceuticals
Add Stock
Add Another

Suven Pharmaceuticals Share Price FAQs

Suven Pharmaceuticals share price data is sourced from NSE/BSE and may be delayed. It is displayed for informational purposes only and does not constitute investment advice or a recommendation to buy or sell.

Trusted by 2 Crore+ Indians for their wealth-building needs. SEBI Registered Broker. SEBI Reg No. INZ000315837